Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Provides Additional Operational and OTC Markets UpdatesJuly 31, 2020

Emmaus provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020

Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™July 29, 2020

Emmaus announced today that the EMA issued scientific advice to Emmaus regarding the clinical development pathway for Xyndari™ for the treatment of sickle cell disease.

Emmaus Life Sciences Accelerates Middle East and North Africa (MENA) Growth Strategy with Opening of its Dubai OfficeJuly 23, 2020

Emmaus announced today the opening of its regional office in Dubai. The Dubai office will be utilized to enhance Emmaus’ relationships with clinicians and patient groups at major hospitals and other government-sponsored health care facilities in communities throughout the Middle East and North Africa (MENA) region.

Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for DiverticulosisJuly 16, 2020

Emmaus Life Sciences, Inc. is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of HealthJune 29, 2020

Emmaus Life Sciences, Inc. announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial distribution and sale of Endari® in Israel.